Analyzing Synaptogenix (NASDAQ:TAOX) and Endonovo Therapeutics (OTCMKTS:ENDVD)

Endonovo Therapeutics (OTCMKTS:ENDVD) and Synaptogenix (NASDAQ:TAOX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Endonovo Therapeutics and Synaptogenix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A
Synaptogenix	N/A	N/A	-$12.77 million	($20.16)	-0.21

Endonovo Therapeutics has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Endonovo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Endonovo Therapeutics and Synaptogenix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%
Synaptogenix	N/A	-240.92%	-150.03%

Risk & Volatility

Endonovo Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.

Insider and Institutional Ownership

10.3% of Synaptogenix shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Comparatively, 2.7% of Synaptogenix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Endonovo Therapeutics and Synaptogenix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	0.00
Synaptogenix	1	0	0	0	1.00

Given Endonovo Therapeutics’ higher possible upside, analysts plainly believe Endonovo Therapeutics is more favorable than Synaptogenix.

Summary

Endonovo Therapeutics beats Synaptogenix on 7 of the 12 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.